GRHL2

Across TCGA pan-cancer cohorts, GRHL2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of GRHL2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GRHL2 RNA is repressed in tumor relative to normal tissue. In most cancer types GRHL2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and BLCA are the cancer types where GRHL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRHL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	II,III,IV	−3.530	<.001	12	view →
KIRP	Female	All	−3.286	<.001	11	view →
BLCA	All	All	+2.216	<.001	11	view →
COAD	Male	IV	+1.306	<.001	10	view →
LUSC	Male	III,IV	+1.882	<.001	8	view →
LUAD	Male	All	+0.822	<.001	8	view →
THCA	All	II,III,IV	−0.514	<.001	8	view →
STAD	Male	All	+1.611	<.001	7	view →
UCEC	All	All	+2.829	<.001	6	view →
BRCA	All	II,III,IV	+1.361	<.001	6	view →
CHOL	Male	All	+4.091	<.001	4	view →
LIHC	Male	All	−0.464	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

GRHL2–KIRC

Open the KIRC breakdown →